Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.085 +0.125 (+13.02%)
Streaming Delayed Price Updated: 12:42 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Lineage Cell Therapeutics: Q4 Earnings Insights
Lineage Cell Therapeutics (AMEX:LCTX) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Lineage Cell Therapeutics's Earnings: A Preview
Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 348 companies hit new 52-week lows. Significant Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was... 
Via Benzinga
Lineage to Present at B. Riley Securities 2022 Virtual Oncology Conference on January 27, 2022
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Present at H.C. Wainwright Bioconnect Virtual Conference
From Lineage Cell Therapeutics, Inc.
Via Business Wire
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026
Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the... 
Via FinancialNewsMedia
38 Stocks Moving In Monday's Mid-Day Session
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF... 
Via Benzinga
65 Biggest Movers From Yesterday
Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... 
Via Benzinga
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases
Lineage Cell Therapeutics Inc (NYSE: LCTX) has entered into an exclusive worldwide collaboration and license agreement with Roche Holdings AG's (OTC: RHHBY)... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
The weekend break is over and that means it's time to get back to work with the biggest pre-market stock movers for Monday! 
Via InvestorPlace
Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Reports Third Quarter 2021 Financial Results and Highlights Progress From Clinical Cell Therapy Programs
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Reports Fourth Case of Retinal Tissue Restoration With OpRegen®
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 10, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
OpRegen® Clinical Data Presented at 125th Annual American Academy of Ophthalmology Meeting by Michael S. Ip, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy
Photo by Daniil Kuželev on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed
Lineage Cell Therapeutics (AMEX:LCTX) brought in sales totaling $512.00 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 0.43%, resulting... 
Via Benzinga
Lineage to Be Featured in B. Riley Securities Fall 2021 “Growth Biotech Best Ideas” Virtual Series on October 18, 2021
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage to Present at the 2021 Cantor Virtual Global Healthcare Conference on September 27, 2021
From Lineage Cell Therapeutics
Via Business Wire
Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
38 Stocks Moving In Wednesday's Mid-Day Session
Gainers Indaptus Therapeutics, Inc. (NASDAQ: INDP) shares jumped 177.2% to $19.60 after the company announced the United States Patent and Trademark Office has issued a notice of... 
Via Benzinga
Topics Intellectual Property
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (... 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers DICE Therapeutics, Inc. (NASDAQ: DICE) shares surged 117% to settle at $36.89 on Wednesday as the company priced its IPO at $17 per share. PROCEPT BioRobotics Corporation... 
Via Benzinga
Topics Initial Public Offering
Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Announces Appointment of General Counsel
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2021 Earnings Call Transcript
LCTX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.